- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06345287
Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC
March 28, 2024 updated by: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related Head and Neck Squamous Cell Carcinoma
The aim of this study is to develop an adaptive radiation therapy plan for locally advanced head and neck squamous cell carcinoma receiving induction therapy containing immunotherapy and chemotherapy.
The therapy plan is based on clinical remission, in order to reduce treatment-related toxic side effects without sacrificing clinical efficacy and improve the quality of life of patients.
Study Overview
Status
Recruiting
Conditions
Detailed Description
Induction chemotherapy combined with immunotherapy has shown promising efficacy in locally advanced head and neck cancers.
However, the appropriate dose and range of the following radical radiotherapy treatment remains unknown.
Eligibility patients were assigned to three arms depending on the degree of clinical remission: clinical complete response (radiotherapy 60Gy + concurrent chemotherapy + immunotherapy maintenance), deep partial response (radiotherapy 66Gy + concurrent chemotherapy + immunotherapy maintenance, non-deep partial response (radiotherapy 70Gy + concurrent chemotherapy + immunotherapy maintenance).
Progression-free survival, overall survival, and treatment-related toxicity would be calculated to evaluate the efficacy of treatments.
Study Type
Interventional
Enrollment (Estimated)
133
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yang Meng
- Phone Number: 13359595417
- Email: YangMeng@pumc.edu.cn
Study Locations
-
-
-
Beijing, China
- Recruiting
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, CAMS & PUMC
-
Contact:
- Jingbo Wang, Doctor
- Phone Number: 15811166516
- Email: wangjingbo303@yahoo.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Head and neck squamous cell carcinoma patients who undergo 2-4 cycles of induction chemotherapy and immunotherapy and plan to undergo radical radiotherapy treatment ( after MDT evaluation and communication with the patient, surgery is not recommended to preserve organ function, or the patient refuses surgery );
- Age range from 18 to 75 years old;
- Squamous cell carcinoma of the head and neck confirmed by pathological tissue biopsy;
- Clinical staging is T1-2N2-3M0, T3-4N0-3M0 (AJCC 8th edition);
- HPV or P16 (-);
- ECOG score 0-1 points;
- No contraindications to immunotherapy and radiotherapy;
- The functional level of the main organs meets the following standards:1) The blood routine examination standards need to meet: WBC ≥ 3.0 × 109/L, ANC ≥ 2.0 × 109/L, PLT ≥ 100 × 109/L, HGB ≥ 90g/L (no blood transfusion or blood products within 14 days, no use of G-CSF or other hematopoietic stimulating factors correction);2) Biochemical examination must meet the following standards: TBIL ≤ 2.0 × ULN, ALT, AST ≤ 2.5 × ULN, BUN and CRE ≤ 1.5 × ULN, or endogenous creatinine clearance rate ≥ 60ml/min (Cockcroft Gout formula);3) Good coagulation function: defined as international standardized ratio (INR) or prothrombin time (PT) ≤ 1.5 times ULN; If the subject is receiving anticoagulant treatment, as long as the PT is within the intended range of use of the anticoagulant drug;4) The myocardial enzyme spectrum is within the normal range;
- Women of childbearing age must have taken reliable contraceptive measures, or have undergone pregnancy tests (serum or urine) within 7 days before enrollment, and the results are negative. They must be willing to use effective methods of contraception during the treatment period and within 2 months thereafter. For male participants whose partners are women of childbearing age, effective methods of contraception should be used during and within 2 months after treatment;
- Voluntarily participate in this study, sign an informed consent form, have good compliance, and cooperate with follow-up.
Exclusion Criteria:
- Previous or concurrent incurable malignant tumors in other parts, except cured skin basal cell carcinoma, cervical carcinoma in situ, thyroid papillary carcinoma and superficial bladder cancer;
- Suffering from any active autoimmune disease or having a history of autoimmune diseases (such as interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism (can be included after normal hormone replacement therapy); Asthma patients who suffer from vitiligo or have completely relieved childhood asthma and do not require any intervention in adulthood can be included, while asthma patients who require medical intervention with bronchodilators cannot be included;
- Suffering from uncontrolled cardiovascular diseases: Grade II or above myocardial ischemia or myocardial infarction, poorly controlled arrhythmias (including QTc interval ≥ 470 ms); According to NYHA standards, patients with grade III-IV cardiac dysfunction or those with left ventricular ejection fraction (LVEF)<50% indicated by echocardiography; Have experienced myocardial infarction within one year;
- Active infection or unexplained fever exceeding 38.5 ℃ during screening or before first administration (according to the researcher's judgment, subjects with fever caused by tumors can be included in the study);
- People with congenital or acquired immune deficiency (such as HIV infected people), active hepatitis B (HBV-DNA ≥ 104 copies/ml) or hepatitis C (hepatitis C antibody is positive, and HCR-RNA is higher than the detection limit of the analytical method);
- Previously received other PD-1 antibody treatments or other immunotherapies targeting PD-1/PD-L1;
- Known to be allergic to cisplatin, macromolecular protein preparations, or any anti PD-1 antibody component;
- If the subject undergoes major surgery without tumor treatment, the toxic reactions and/or complications caused by the surgical intervention must be fully recovered before starting treatment;
- Pregnant or lactating women;
- In the investigator's judgment, the subjects had other factors that might have led to their forced discontinuation of the study, such as other serious medical conditions (including mental illness) requiring concomitant treatment, serious abnormalities in laboratory test values, or family or social factors that might have affected the safety of the subjects or the circumstances of the trial data collection.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: clinical complete response
radiotherapy 60Gy + concurrent chemotherapy + immunotherapy maintenance
|
concurrent chemoradiotherapy (60Gy) after induction therapy
immunotherapy maintenance with anti-PD-1 or PDL1antibody every three weeks for 1 year after radiotherapy
|
Experimental: deep partial response
radiotherapy 66Gy + concurrent chemotherapy + immunotherapy maintenance
|
immunotherapy maintenance with anti-PD-1 or PDL1antibody every three weeks for 1 year after radiotherapy
concurrent chemoradiotherapy (66Gy) after induction therapy
|
Experimental: non-deep partial response
radiotherapy 70Gy+ concurrent chemotherapy + immunotherapy maintenance
|
immunotherapy maintenance with anti-PD-1 or PDL1antibody every three weeks for 1 year after radiotherapy
concurrent chemoradiotherapy (70Gy) after induction therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival
Time Frame: 2 years
|
defined as the time from random assignment to documented local or regional relapse, distant metastasis, or death from any cause, whichever occurred first after 2 years of treatment
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: 2 years
|
defined as the time from random assignment to death from any cause or censored at the date of last follow-up
|
2 years
|
Deep partial response
Time Frame: 2 years
|
Defined as maximum tumor diameter retreat ≥ 50%
|
2 years
|
Local-Regional failure survival
Time Frame: 2 years
|
defined as the time from random assignment to documented local or regional relapse, whichever occurred first after 2 years of treatment
|
2 years
|
Toxicity Adverse events
Time Frame: 2 years
|
Analysis of acute and late adverse events (AEs) are evaluated.
Numbers of patients of treatment-related adverse events (acute toxicity) and late radiation toxicities were assessed by NCI-CTCAE v5.0
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Junlin Yi, Doctor, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, CAMS & PUMC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2024
Primary Completion (Estimated)
December 31, 2025
Study Completion (Estimated)
December 31, 2026
Study Registration Dates
First Submitted
March 28, 2024
First Submitted That Met QC Criteria
March 28, 2024
First Posted (Actual)
April 3, 2024
Study Record Updates
Last Update Posted (Actual)
April 3, 2024
Last Update Submitted That Met QC Criteria
March 28, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 24/018-4298
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Cancer
-
Robert FerrisAmgenCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditionsUnited States
-
Assiut UniversityRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and NeckEgypt
-
Mayo ClinicRecruitingCancer Head Neck | Cancer Neck | Cancer, HeadUnited States
-
IRCCS Policlinico S. MatteoNestlé Health Science Spain; Akern SrlCompletedHead-neck CancerItaly
-
University of California, San FranciscoCompleted
-
Chinook Therapeutics, Inc. (formerly Aduro)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedHead And Neck CancerUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
Radboud University Medical CenterUnknown
-
WepromNeptuneActive, not recruitingMetastatic Colorectal Cancer | Metastatic Head and Neck CancerFrance
Clinical Trials on radical radiotherapy (60Gy)
-
Zhejiang Cancer HospitalRecruitingNeoplasm Metastasis | Nasopharyngeal CancerChina
-
International Atomic Energy AgencyTata Memorial Centre; University of Maryland, College Park; Centro de Lucha contra... and other collaboratorsUnknownSquamous Cell Carcinoma of the Head and NeckIndia, Argentina, Cuba, Indonesia, Pakistan, Philippines, South Africa, Thailand, Uruguay
-
Guangdong Provincial People's HospitalRecruitingHead and Neck Cancer | Radiotherapy; Adverse EffectChina
-
xuexin heRecruitingBreast Cancer | OligometastasisChina
-
Tongji HospitalChanghai Hospital; Sun Yat-sen University; Cancer Institute and Hospital, Chinese... and other collaboratorsNot yet recruiting
-
CCTU- Cancer ThemeUniversity of Cambridge; Microsoft ResearchRecruiting
-
Rete Oncologica Piemonte, Valle d'AostaAzienda Ospedaliera Città della Salute e della Scienza di Torino; Compagnia...Completed
-
University Hospital, GhentRecruiting
-
Institut Català d'OncologiaUnknownCarcinoma, Non-Small-Cell Lung | Neoplasm MetastasisSpain
-
University of Rome Tor VergataSuspended